• Rush Now Enrolling Patients in Phase 2 Trial Testing Opdivo Combo Therapies for Advanced Renal Cell Carcinoma
  • FDA Chalks Up a First by Approving Keytruda for Cancers with Specific Genetic Features
  • FDA Grants Priority Review to Keytruda for Heavily-treated Stomach Cancer Patients
  • Nanoparticle Shows Promise in Engaging Immune System to Fight Tumors
  • FDA Approves Keytruda as First- and Second-Line Therapy for Bladder Cancer
  • Progenitor Develops 2 New Gene Editing Tools to Improve Off-the-Shelf Cellular Immunotherapies
  • Vaccines Based on Immunotherapies Being Tested in Phase 2 Trials in Brain Cancer
  • OSE-172 Continues to Show Promising Activity Against Multiple Cancer Models, Researchers Say
  • Granzyme B Protein May Help ID Cancer Patients Who Respond to Immunotherapy Treatments
  • NantKwest, NantCell to Test NANT Vaccine in Phase 1/2 Trial for Pancreatic Cancer Patients
  • Tecentriq Fails to Improve Survival in Previously Treated Metastatic Bladder Cancer Patients in Phase 3 Study
  • Inovio, Regeneron Plan Clinical Trial of Triple-Combo Immunotherapy for Brain Tumors